By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GéopolitiqueOne-OffSanté et médecine3a
Manifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleOui 53.5%
Prévisionnistes
5
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 20 heures
Obsolète18 nov. 22, 02:41 UTC1 janv. 30, 08:00 UTC
Tendances
Règles
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
